

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 37/00, C07K 3/00, 13/00 C07K 15/00, 17/00		A1	(11) International Publication Number: WO 91/15219 (43) International Publication Date: 17 October 1991 (17.10.91)
(21) International Application Number: PCT/US91/02363		(74) Agents: SIBLEY, Kenneth, D. et al.; Bell, Seltzer, Park & Gibson, P.O. Drawer 34009, Charlotte, NC 28234 (US).	
(22) International Filing Date: 5 April 1991 (05.04.91)		(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).	
(30) Priority data: 505,934 6 April 1990 (06.04.90) US		Published <i>With international search report.</i>	
(71) Applicant: WAKE FOREST UNIVERSITY [US/US]; Office of Research Development, 300 South Hawthorne Road, Winston-Salem, NC 27103 (US).			
(72) Inventors: BERBERIAN, Paul, A. ; 705-C South Marshall Street, Winston-Salem, NC 27101 (US). TYTELL, Michael ; 431 Flynt Valley Road, Winston-Salem, NC 27104 (US). GOWER, David, J. ; Post Office Box 26307, S. Pavilion, 4FP-200, Oklahoma City, OK 73126 (US).			

(54) Title: METHOD OF TREATMENT WITH HSP70

(57) Abstract

A method of combating mortality in a cell or tissue under stress is disclosed. The method comprises contacting hsp70 to the cell or tissue in an amount effective to enhance the survival of that cell or tissue. The method may be employed in the combating of atherosclerosis, restenosis after angioplasty, and nerve damage in human or animal subjects in need of such treatment. A pharmaceutical composition comprising a therapeutically effective amount of hsp70 in a pharmaceutically acceptable formulation is also disclosed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finnland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BC	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LJ	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

METHOD OF TREATMENT WITH HSP70

Field of the Invention

The present invention relates to methods of enhancing the survivability of cells and tissues by treating the same with exogenous hsp70.

5

Background of the Invention

Heat shock proteins (hsps) are highly conserved constitutive and induced proteins found in cells from bacteria to human beings. S. Lindquist, Ann. Rev. Biochem 55, 1151 (1986). The constitutive hsps are critical to many diverse cellular functions. The most ubiquitous and best studied hsp family, the group of hsp's with molecular weights close to 70,000 daltons (hsp70), has been shown to assist in translocation of proteins into the endoplasmic reticulum and mitochondria, R. Deshais et al., Nature 332, 800 (1988), W. Chirico et al., Nature 332, 805 (1988). Hsp 70 also has been implicated as the clathrin-uncoating ATPase, T. Chapell et al., Cell 45, 3 (1986). Potential structural functions of other hsps include: linking the actin cytoskeleton to the plasmalemma, S. Koyasu et al., Proc. Natl. Acad. Sci. USA 83, 8054 (1986); specifically binding saturated fatty acids, P. Guidon and L. Hightower, Biochemistry 25, 3231 (1986); P. Guidon and L. Hightower, J. Cell Physiol. 128, 239 (1986), and as

-2-

components of some steroid binding receptors. E. Baulieu and M. Catelli, Alan R. Liss, Inc., New York, 275 (1989). These proteins also appear to act as antigens in anti-bacterial, D. Young et al., Proc. Natl. Acad. Sci. USA 85, 4267 (1988); A. Mehltret et al., Biochem. Soc. Trans. 16, 721 (1988), and autoimmune reactions. S. Minota et al., J. Exp. Med. 168, 1475 (1988), S. Minota et al., J. Clin. Invest. 81, 106 (1988). Several other functions have been suggested as well. See S. Lindquist, Ann. Rev. Biochem 55, 1151 (1986), M. Schlesinger et al., Cold Spring Harbor Laboratory, 1982, M. Pardue et al., Alan R. Liss, Inc. (1989), M. Schlesinger, J. Cell Biol. 103, 321 (1986), E. Craig, CRC Critical Reviews in Biochemistry, Vol. 18, no. 3, 239 (1985).

The inducible forms of hsp's are elicited by a variety of stressors, including elevated temperature, M. Schlesinger et al., Cold Spring Harbor Laboratory, 1982, heavy metals, M. Schlesinger et al., Alan R. Liss, Inc., 137 (1989), amino acid analogs, P. Kelley and M. Schlesinger, Cell 15, 1277 (1978), L. Hightower, J. Cell. Physiol. 102, 407 (1980), oxidative radicals, M. Ashburner, Chromosoma 31, 356 (1970), J. Compton and B. McCarthy, Cell 14, 191 (1978) ischemia or return from anoxia, S. Guttman, Cell 22, 299 (1980), M. Ashburner and J. Bonner, Cell 17, 241 (1979), mechanical trauma, L. Hightower and F. White, Cold Spring Harbor Laboratory, 369 (1982), D. Gower et al., J. Cell Biol. 103, 291 (1986), and abnormal proteins. J. Ananthan et al., Science 232, 522 (1986). The unifying functional characteristic is that they act to maintain normal cellular function under non-ideal conditions.

The functional importance of hsp's to cells under stress extends to the arterial wall and atherosclerosis. The developing plaque involves histological and biochemical changes in the composition of the arterial wall, R. Ross, N. Eng. J. Med. 314, 488 (1986). In chronically stressed atherosclerotic plaque

-3-

cells, hsp alterations may have serious implications. As an example, one general effect of hsps is to stabilize membranes of cells, R. Shiver et al., Eur. J. Cell Biol. 46, 181 (1988), and it has been suggested that stabilization of arterial lysosomal membranes may facilitate plaque cells to entrap lipids, J. Berthet et al., Biochem. J. 50, 182 (1951), C. deDuve, Harvey Lectures 59, 49 (1965), P. Berberian et al., Fed. Proc. 43, 711 (1984). Cell stabilization by hsps additionally may help to determine the relative survival of cells within various regions of the developing plaque, while its relative deficiency may define areas vulnerable to necrosis.

There is evidence that hsps can be exchanged between cells. L. Hightower and P. Guidon, J. Cell. Physiol. 138, 257 (1989), M. Tytell et al., Brain Res. 363, 161 (1986). Thus, it is possible that hsps' effects may not be limited to the stressed cell synthesizing them. However, no one has tested the effect of exogenously added hsps on cell survival. The present invention is based on our findings after undertaking such tests.

Summary of the Invention

A first aspect of the present invention is a method of combating mortality in a cell under stress. The method comprises contacting hsp70 to the cell in an amount effective to enhance the survival of that cell.

A second aspect of the present invention is a method of combating mortality in a tissue under stress, such as arterial tissue. The method comprises contacting hsp70 to the tissue in an amount effective to enhance the survival of cells residing in that tissue. The tissue may be treated in vivo or in vitro. Among other things, this method is useful for preserving organs for transplant.

A third aspect of the present invention is a method of combating atherosclerosis in a human or animal

-4-

subject in need of such treatment. The method comprises administering the subject hsp70 in an amount effective to reduce necrosis in arterial plaques residing in the subject.

5 A fourth aspect of the present invention is a method of combating arterial restenosis after angioplasty in a human or animal subject in need of such treatment comprising administering arterial tissue residing in the subject in need of such treatment hsp70 in a restenosis-combating amount.

10 15 A fifth aspect of the present invention is a method of combating nerve damage in a human or animal subject in need of such treatment, comprising administering the subject hsp70 in an amount effective to enhance the survival of nerve cells under stress.

A sixth aspect of the present invention is a pharmaceutical composition comprising a therapeutically effective amount of hsp70 in a pharmaceutically acceptable formulation.

20 A seventh aspect of the present invention is the use of hsp70 for the preparation of a pharmaceutical formulation for the combating of mortality in arterial tissue.

25 An eighth aspect of the present invention is the use of hsp70 for the preparation of a pharmaceutical formulation for the combating of mortality in nerve tissue.

Brief Description of the Drawings

30 Figure 1 illustrates the structure-linked latency of lysosomal enzymes versus viability for isolated cells without added hsp70. Data represent pooled normal (open square) and diseased (closed square) monkey aortic cell values ($n = 23$ across all temperatures tested ($r = 0.85$)).

35 Figure 2 illustrates the effect of temperature on arterial cell viability (2a) and structure-linked lysosomal latency (2b) without added hsp70. Means of 6

-5-

aortas +/- s.e.m. are shown. Figure 2a illustrates that a significant ($p < 0.0005$) decline in viability occurs with increased temperature of incubation; figure 2b illustrates that a significant ($p < 0.004$) decline in lysosomal latency occurs with increased temperature of incubation.

Figure 3 illustrates the dose-dependent effect of hsp70 on viability (including time zero and with no added hsp70). Means of 4 aortas +/- S.E.M. are shown. A significant difference in viability occurs at a dose of 10 ng/ 10^3 cells ($p < 0.05$), with no significant increase observed with a ten-fold higher dose.

Figure 4 illustrates the temperature-dependent effect of hsp70 on arterial cell viability. Each temperature was tested with and without 10 ng hsp70 per 10^3 cells. Means of 6 samples of cells from aortas +/- s.e.m. are shown. Comparison between all treated versus untreated samples showed a significant ($p < 0.05$) increase in viability with added hsp at 37°C.

Figure 5 illustrates the temperature-dependent effect of hsp70 on structure-linked latency of lysosomal enzymes. Means of 6 aorta samples +/- s.e.m. are shown. No significant increase occurred with exogenous hsp.

Figure 6 illustrates the effect of intravitreal injection of hsp70 in the right eye on retinal sensitivity to light damage. The right-left differences in photoreceptor area (square μm) are shown. Significant prevention of photoreceptor destruction occurred at the high dose of hsp70.

30 Detailed Description of the Invention

Cells of any origin may be treated by the method of the present invention, including animal, plant, and bacterial cells. Cells may be treated in vitro or in vivo. Likewise, tissues of any origin, including animal and plant tissue, may be treated by the method of the present invention either in vitro or in vivo. Animal cells and tissues are preferred for carrying out the

-6-

present invention, with mammalian (e.g., dog, cat, human) cells and tissue particularly preferred. The term "animal" as used herein, refers to the subjects of veterinary medicine, such as dog, cat, cow, pig, and horse.

Cells and tissue which are under stress are treated with hsp70 to combat mortality. For example, cells which are maintained in culture (e.g., for the purpose of producing proteins or other materials from the cells) or tissue which is maintained in culture (e.g., complete organs such as heart, lung, liver or kidney prior to transplant) may be considered as "under stress" for the purpose of practicing the present invention. For example, organs could be immersed in a solution containing HSP70, or a larger organ perfused through its vasculature, with an HSP70 solution. The HSP70 would be taken up by the cells of the organ, making them more resistant to the lack of blood, nutrients and other needed substances that exists once they are removed from the body. Likewise, the HSP70 could be included in a reperfusion solution to combat tissue reperfusion injury. The HSP70 may be added to known solutions and used in accordance with procedures known to those skilled in the art for these purposes. Such solutions and procedures are disclosed in U.S. Patent No. 4,920,044, titled "Intracellular Flush Solution for Preserving Organs", U.S. Patent No. 4,879,283 titled "Solutions for the Preservation of Organs", U.S. Patent No. 4,873,230 titled "Composition for the Preservation of Organs", and U.S. Patent No. 4,798,824 titled "Perfusate for the Preservation of Organs". Applicants intend the disclosures of these and all other patents cited herein to be incorporated herein by reference.

Tissue under stress in vivo may also be treated. For example, arterial and myocardial tissue may be treated by administering hsp70 during by-pass surgery to enhance the survivability of cells in that tissue.

-7-

Cardiac ischemia may be treated by administering hsp70 about the time of myocardial infarction to enhance the survivability of cells in those tissues. The kidney may be protected from damage from toxic substances such as 5 the antibiotic Gentamicin by the administration of hsp70. Arterial tissue may be administered hsp70 during laser angioplasty and atherectomy to reduce damage to these tissues arising from such procedures.

Nerve tissue (i.e., peripheral nerve and 10 central nerve) which is under stress in vivo may also be treated by the method of the present invention. For example, peripheral nerves which are severed are subject to retrograde degeneration, which degeneration may culminate in death of the nerve cell, or soma, if too 15 great a portion of the nerve's axon is distal to the site of the cut. If degeneration does not culminate in cell death, then an opportunity exists for the nerve to regenerate. Thus, hsp70 may be administered to such nerve tissue, through administration to the host animal, 20 to combat cell mortality which may result from the severing of the peripheral nerve.

Nerve tissue may also be subject to anoxic stress in vivo. For example, anoxic stress may arise 25 from a stroke or burst aneurism which damages nerve tissue by depriving the tissue of blood. When central nerve tissue is so damaged, the damage typically occurs in a watershed pattern in relation to the blood vessels: tissue closest the damaged supply vessel is most severely damaged; tissue furthest from the damaged vessel which is 30 supplied by other vessels is least severely damaged; tissue intermediate of these extremes shows intermediate damage. Afflicted subjects are administered hsp70 to combat mortality in cells subject to this type of stress.

As noted above, the present invention may be 35 employed to combat restenosis after angioplasty. Angioplasty is a procedure for dilating arteries which are occluded or blocked. In a typical transluminal

-8-

balloon angioplasty procedure, a catheter which carries an inflatable dilation balloon at the distal end is employed to reshape a partially occluded artery. The balloon is inserted in the deflated condition in the restricted portion of the artery and inflated so that the occluded lumen is reshaped by the dilation balloon to allow better passage of blood. The obstructing material is neither dislocated nor removed from the vessel, but rather pressed against the wall. The wall, in turn, is stretched to accommodate the previously obstructing material. After the lumen has been reshaped, the dilation balloon is deflated and removed. The site of the formed obstruction may, however, become reoccluded when/if the vessel returns to its previous configuration: a phenomenon known as "restenosis." A variety of angioplasty procedures and instruments are known. See, e.g., U.S. Patent Nos. 4,838, 269 and 4,794,928 (the disclosures of which are to be incorporated herein by reference). A subject in need of treatment to prevent restenosis (i.e., either during angioplasty or after angioplasty prior to the onset of restenosis) may be treated by administering hsp70 to the lumen of the vessel which has been reshaped (e.g., by intraveneous injection or intraarterial injection). Any administration which places hsp70 into the bloodstream of the subject or at the site of treatment is suitable, but preferably the administration procedure will direct the hsp70 to the particular site of the angioplasty (i.e., the vessel wall which has been reshaped). For example, the hsp70 may be applied directly to the site of treatment by means of a sweating balloon catheter (i.e., an angioplasty balloon which is perforated so as to administer hsp70 through the perforations to the arterial cell wall during angioplasty).

Skin tissue under stress due to wounds, burns, ulcers, infections, and other types of traumatic injury may be treated by the method of the present invention.

-9-

For such purposes HSP70 may be administered by topical application to the skin in the form of a salve or cream to enhance repair and healing of the tissue. Tissues may also be under stress due to chemotherapeutic treatment, as in cancer chemotherapy. In such cases HSP70 may be administered subsequent to the chemotherapeutic treatment as a "rescue" agent.

Hsp70 is a member of the heat shock protein (or "hsp") family, which are produced when cells or organisms are exposed to elevated temperatures. This response has been observed in essentially all organisms to date. See generally S. Lindquist, The Heat-Shock Response, Ann. Rev. Biochem. 55, 1151 (1986). For example, hsp70 has been found in plants. See, e.g., J. Marshall et al., Proc. Natl. Acad. Sci. USA 87, 374 (1990). The hsp70 group is the most highly conserved member of the hsp family. For example, the human protein is 73% identical to the *Drosophila* protein and is 50% identical to the corresponding *Escherichia coli* protein dnaK. See B. Bukau et al., DnaK and GroE Proteins Play Roles in *E. coli* Metabolism at Low and Intermediate Temperatures as Well as at High Temperatures, in Stress-Induced Proteins, 27 (1989) (published by Alan R. Liss, Inc.). Many of the differences are merely homologous substitutions, and there are regions of homology which those in the field consider to be extraordinary. S. Lindquist, supra at 1155-56.

Within some species, the term "hsp70" itself denotes a family of closely related proteins, all found in that species. In *Saccharomyces cerevisiae*, strains bearing certain hsp70 mutations are nonviable, but viability can be restored by altering the transcriptional regulation of the remaining genes. See E. Craig et al., Complex Regulation of Three Heat Inducible hsp70 Related Genes in *Saccharomyces cerevisiae*, in Stress-Induced Proteins, 51 (1989). In view of the biological interchangeability and homology, any member of the hsp70

-10-

family within a species is contemplated as useful in practicing the present invention.

As to species of origin, in view of the highly conserved nature of the hsp70 family among broadly divergent species, hsp70 from any species of origin is contemplated as useful in practicing the present invention (numerous references to hsp70 are set forth above, the disclosures of which are to be incorporated herein by reference). Thus, animal, plant (e.g., *Pisum sativum*), and bacterial hsp70 are all contemplated as useful for treating cells or tissue of any origin in practicing the present invention. It is, nevertheless, contemplated that an hsp70 of related origin to the cell or tissue being treated will be preferred for practicing the present invention. For example, plant hsp70 is contemplated as preferred for treating plant cells or tissue, animal hsp70 is contemplated as preferred for treating animal cells or tissue, mammalian hsp70 is contemplated as preferred for treating mammalian cells or tissue, and so on.

The term "HSP 70" is intended to include active fragments, subunits, and artificial analogs thereof. Those regions of the HSP70 molecule which show the greatest structural similarity between different organisms and species are contemplated to be the key sources of its biological activity. Therefore, fragments of the native protein, analogs which contain substitution mutations, deletion mutations, or addition mutations, or even entirely synthetic analogs of HSP70, can be prepared in accordance with known procedures and tested in a routine manner for their ability to increase the metabolic stress tolerance of a sample of tissue or cells using the procedures described herein.

Dose of hsp70 will vary depending on the particular route of administration used. In general, for systemic, local, and *in vitro* treatments, an overall dose range of from about .02 milligrams to about 20 milligrams

-11-

hsp70 per gram of cells or tissue being treated is contemplated. It is further contemplated that, for local treatments, the maximum doses will be about twenty times greater than the maximum systemic doses.

5 HSP70 may be administered concurrently or in combination with other therapeutic agents. For example, the HSP70 may be combined with another agent known to protect cells from acute injury. Such agents include anti-oxidants or free radical scavengers such as vitamins 10 C and E and superoxide dismutase when the damaging event works through the production of reactive oxygen molecules. When the mechanism of cell damage involves the influx of extracellular calcium, the other agent might be one which reduces the influx of excess calcium 15 ions (e.g., in brain tissue) such as dextrophan and MK-801. When the mechanism of damage is myocardial infarction, the other agent might be one that removes the blockage of blood flow to the heart muscle, such as tissue plasminogen activator (TPA) and streptokinase.

20 Hsp70 may be administered per se or in the form of a pharmaceutically acceptable salt. When used in medicine, the salts of hsp70 should be both pharmacologically and pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be 25 used to prepare the free active compound or pharmaceutically acceptable salts thereof and are not excluded from the scope of this invention. Such pharmacologically and pharmaceutically acceptable salts include, but are not limited to, those prepared from the 30 following acids: hydrochloric, hydrobromic, sulphuric, nitric, phosphoric, maleic, acetic, salicylic, p-toluenesulfonic, tartaric, citric, methanesulphonic, formic, malonic, succinic, naphthalene-2-sulphonic and benzenesulphonic. Also, pharmaceutically acceptable 35 salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts of the carboxylic acid group. Thus, the present invention also

-12-

provides pharmaceutical formulations, both for veterinary and for human medical use, which comprise hsp70 together with one or more pharmaceutically acceptable carriers thereof and optionally any other therapeutic ingredients.

5 The carrier(s) must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not unduly deleterious to the recipient thereof.

10 The formulations include those suitable for oral, rectal, topical, nasal, ophthalmic or parenteral (including subcutaneous, intramuscular and intravenous) administration, all of which may be used as routes of administration for practicing the present invention. Other suitable routes of administration include 15 intrathecal administration directly into spinal fluid (CSF), direct injection onto an arterial surface to prevent re-stenosis, and intraparenchymal injection directly into targeted areas of an organ. Formulations suitable for parenteral administration are preferred.

20 The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active compound into association with a carrier which constitutes one or more accessory ingredients. In general, the formulations are 25 prepared by uniformly and intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into desired formulations.

30 Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets or lozenges, each containing a predetermined amount of the potentiating agent as a powder or granules; as liposomes 35 containing hsp70; or as a suspension in an aqueous liquor or non-aqueous liquid such as a syrup, an elixir, an emulsion or a draught.

-13-

A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine, with the active compound being in a free-flowing form such as a powder or granules which is optionally mixed with a binder, disintegrant, lubricant, inert diluent, surface active agent or dispersing agent. Molded tablets comprised of a mixture of the powdered active compound with a suitable carrier may be made by molding in a suitable machine.

A syrup may be made by adding the active compound to a concentrated aqueous solution of a sugar, for example sucrose to which may also be added any accessory ingredient(s). Such accessory ingredient(s) may include flavorings, suitable preservatives, an agent to retard crystallization of the sugar, and an agent to increase the solubility of any other ingredient, such as a polyhydric alcohol, for example glycerol or sorbitol.

Formulations suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the active compound, which is preferably isotonic with the blood of the recipient.

Nasal spray formulations comprise purified aqueous solutions of the active compound with preservative agents and isotonic agents. Such formulations are preferably adjusted to a pH and isotonic state compatible with the nasal mucous membranes.

Formulations for rectal administration may be presented as a suppository with a suitable carrier such as cocoa butter, or hydrogenated fats or hydrogenated fatty carboxylic acids.

Ophthalmic formulations are prepared by a similar method to the nasal spray, except that the pH and isotonic factors are preferably adjusted to match that of the eye.

Topical formulations comprise the active compound dissolved or suspended in one or more media such

-14-

as mineral oil, petroleum, polyhydroxy alcohols or other bases used for topical pharmaceutical formulations. The addition of other accessory ingredients, vide infra, may be desirable.

5 In addition to the aforementioned ingredients, the formulations of this invention may further include one or more accessory ingredient(s) selected from diluents, buffers, flavoring agents, binders, disintegrants, surface active agents, thickeners, 10 lubricants, preservatives (including antioxidants) and the like.

15 The following Examples are provided to illustrate the present invention, and should not be construed as limiting thereof. Temperatures are given in degrees Celsius unless otherwise indicated.

EXAMPLE 1

Effect of hsp70 on survival of Aortic Cells from Normal and Atherosclerotic Cynomolgus Macaques

A. METHODS

20 1. Materials.

Low calcium (0.2 mM) Hank's balanced salt solution (LC-HBSS) supplemented with essential and nonessential amino acids, penicillin (100 IU/ml), streptomycin (100 µg/ml), and phenol red indicator, and 25 special low calcium Hank's balanced salt solution (SL-HBSS) without amino acids or phenol red, where prepared fresh prior to use in accordance with known techniques. See N. Haley et al., Lab. Invest. 37, 287 (1977). Chromatographically purified collagenase and elastase 30 were obtained from Worthington Diagnostics (Freehold, NJ, USA). Soybean trypsin inhibitor (crude) was from Millipore, Inc. (Bedford, MA, USA). The 4-methylumbiferyl-2-acetimido-2-deoxy- β -D-glucopyranoside (MW 379.37) substrate for N-acetyl- β -glucosaminidase 35 (NABA) enzyme activity assays was from Koch-Light Laboratories (Cobnright-Bucks, UK). The hsp70 employed was purified from bovine brain essentially according to

-15-

the procedure of Schlossman et al., 99 J. Cell Biol. 723 (1984). The hsp70 and N27F34 monoclonal antibody were gifts from Dr. Lawrence Hightower (University of Connecticut, Storrs) and Dr. William Welch (University of California, San Francisco), respectively. The horseradish peroxidase-conjugated secondary antibody for Western blot analysis and lactate dehydrogenase, histone H-IIa, and parathyroid hormone for comparison against hsp70 were from Sigma Chemicals (St. Louis, MO, USA).

10

2. Induction of Atherosclerosis.

Eight adult male cynomolgus macaques were obtained from Charles River Laboratories, and housed in individual cages. Five animals were fed an atherogenic diet consisting of 1.0 mg cholesterol/kcal, with 40% of calories from butterfat, 38% of calories from carbohydrates, 22% of calories from protein, and 270 ml water/kg, D. Small et al., J. Clin. Invest. 73, 590 (1984). Three control animals were fed Purina® Monkey Chow. Monkeys were fed these diets ad libitum for 23-27 months. Periodic plasma lipid profiles were determined as a measure of success in induction of hypercholesterolemia (Table 1).

15

20

3. Animal Sacrifice and Cell Isolation.

25

30

35

40

45

50

55

60

65

70

75

80

85

90

95

100

105

110

115

120

125

130

135

140

145

150

155

160

165

170

175

180

185

190

195

200

205

210

215

220

225

230

235

240

245

250

255

260

265

270

275

280

285

290

295

300

305

310

315

320

325

330

335

340

345

350

355

360

365

370

375

380

385

390

395

400

405

410

415

420

425

430

435

440

445

450

455

460

465

470

475

480

485

490

495

500

505

510

515

520

525

530

535

540

545

550

555

560

565

570

575

580

585

590

595

600

605

610

615

620

625

630

635

640

645

650

655

660

665

670

675

680

685

690

695

700

705

710

715

720

725

730

735

740

745

750

755

760

765

770

775

780

785

790

795

800

805

810

815

820

825

830

835

840

845

850

855

860

865

870

875

880

885

890

895

900

905

910

915

920

925

930

935

940

945

950

955

960

965

970

975

980

985

990

995

1000

1005

1010

1015

1020

1025

1030

1035

1040

1045

1050

1055

1060

1065

1070

1075

1080

1085

1090

1095

1100

1105

1110

1115

1120

1125

1130

1135

1140

1145

1150

1155

1160

1165

1170

1175

1180

1185

1190

1195

1200

1205

1210

1215

1220

1225

1230

1235

1240

1245

1250

1255

1260

1265

1270

1275

1280

1285

1290

1295

1300

1305

1310

1315

1320

1325

1330

1335

1340

1345

1350

1355

1360

1365

1370

1375

1380

1385

1390

1395

1400

1405

1410

1415

1420

1425

1430

1435

1440

1445

-16-

soybean trypsin inhibitor. The digestion mix was incubated at 37°C, adding sodium carbonate as needed to maintain neutrality, and shaking in a Dubnoff Metabolic incubator (Fisher, Pittsburgh, PA, USA). Released cells were collected every 30 minutes, separated from the enzyme mixture, washed twice with SL-HBSS for 6 minutes at 3000 rpm, and suspended in 2.0 ml of SL-HBSS at 4°C until all cells were harvested. Individual harvests were pooled, the cell concentrations determined, and the isolate diluted to 10⁶ cells/ml with SL-HBSS. The final diluted isolate was held at 4°C prior to and after a treatment regimen.

4. Confirmation and Characterization of hsp70.

Bovine brain hsp70 was received as a solution of 10 µg/µl in 20 mM HEPES buffer, pH 7.0 and routinely stored at -30°C. The composition was confirmed using Western blot analysis. Samples of protein were separated on 10% polyacrylamide gel under reducing conditions, blotted to nitrocellulose, and reacted with N27F34, a murine monoclonal antibody specific to the 73 kD constitutive and 72 kD inducible hsps. The secondary antibody was horseradish peroxidase-conjugated, rabbit anti-mouse anti-IgG. Final staining was with diaminobenzidine/hydrogen peroxide in Tris buffer, pH 7.2. Relative densities of the identified protein bands were determined using an Ultroscan XL laser densitometer (LKB, Rockville, MD. USA).

5. Induced Stress of Cell Isolates.

Normal and diseased arterial cell isolates were tested for changes in viability and structure-linked latency of lysosomal enzymes, in response to extended stress. Samples of 0.2 ml of cell isolates were placed in sealed 1 ml Eppendorf tubes with 0.01 ml of SL-HBSS with or without hsp70 added. Dose-response for hsp70 was determined using cells exposed to 37°C for 20 hours, with and without 2, 5, 10, or 100 ng hsp70 added per 10³ cells. To determine responses following thermal-induced stress,

-17-

cells were exposed to 23, 37, or 45°C for 20 hours, with or without 10 ng of hsp70 added per 10³ cells. Comparative studies for nonspecific changes due to exogenous protein were performed at 37°C using lactate dehydrogenase, histone H-IIa, and parathyroid hormone, at normal and ten times normal physiological concentrations.

5 6. Assessment of Cell Viability and Lysosomal Membrane Integrity.

Cell viability was determined immediately following the 20 hour test period using 0.4% Trypan blue dye exclusion. Each stored cell suspension was sampled in quadruplicate and examined individually by two investigators. Intact cells versus cell lysis also were noted. Structure-linked latency of lysosomal N-acetyl- β -glucosaminidase (NABA) was calculated as representative of lysosomal membrane integrity. Free and total NABA activities were determined fluorometrically as described previously. See P. Berberian, S. Fowler, Exp. Mol. Pathol. 30, 27 (1979). Briefly, samples of 0.1 ml of experimental aortic cells were suitably diluted in SL-HBSS, and incubated 90 minutes at 37°C with 0.1 ml of 0.50 mM 4-methylumbelliflferone substrate in 250 mM sucrose containing 100 mM sodium citrate buffer, pH 4.8, with (total activity) or without (free activity) 0.1% Triton X-100. Structure-linked latency of lysosomal enzymes was defined by the difference between total and free NABA activity, and was expressed as a percent of total activity, J. Berthet et al., Biochem. J. 50, 182 (1952).

20 7. Statistical Methods.

30 The results were analyzed for differences in cell viability and structure-linked lysosomal enzyme latency using repeated measures ANOVA. Samples were compared for effects of disease versus control aortic cells, dosage of heat shock protein added, and temperature during test incubation. The interrelationship of viability and latency was tested using standard linear regression.

-18-

B. RESULTS1. Dietary Induction of Atherosclerosis

The atherogenic diet induced hypercholesterolemia with subsequent plaque formation, as shown in Table 1. Light and electron microscopic examination of cell isolates from diseased aortas contained a large proportion of lipid-filled foam cells and lipid-enriched smooth muscle cells as well as normal smooth muscle cells. Normal aortas exhibited no lesions, and their respective cell isolates contained primarily normal smooth muscle cells.

TABLE 1

Monkey Blood Lipid Values and Atherosclerosis Grade

15	Monkey No.	Athero-genic Diet	Chol. ¹	HDL ¹	TG ¹	Grade ²	Confluency %
	1	Yes	778	15	16	II-III	70
	2	Yes	572	33	21	II	30
	3	Yes	672	40	92	III	100
20	4	No	112	65	23	0	--
	5	No	142	66	28	0	--
	6	No	183	100	27	0	--

1 Plasma values are from pre-sacrifice, fasted animals, and are expressed as mg/dl. Chol. = total plasma

cholesterol; HDL = total plasma high-density lipoproteins; TG = total plasma triglycerides.

2 Grade: 0 = No lesions; II = Minimally raised atheromatous lesions; III = Significantly raised atheromatous lesions, with fibrosis.

2. Characterization of hsp70.

30 Western blot analysis of the purified hsp70 used in these studies yielded two immunoreactive bands, corresponding to the 73 kD constitutive (estimated 70% of total reactive protein) and 72 kD induced (estimated 30% of total reactive protein) forms of hsp.

-19-

3. Effect of Thermal-Induced Stress Upon Viability and Lysosomal Membrane Integrity of Isolated Cells.

Since data analyses using repeated measures ANOVA did not show any significant differences in test responses between cell isolates from normal and diseased animals, the isolates were considered similar in their response, and the data discussed pooled for analysis ($n = 6$). A linear regression of structure-linked latency of lysosomal enzymes (i.e., lysosomal membrane integrity) versus viability for control (No hsp70) aortic cell isolates ($n = 23$) showed lysosomal membrane integrity and viability were well correlated ($r = 0.85$), regardless of incubation temperature (Fig. 1). Furthermore, viability and lysosomal membrane integrity of control samples both declined significantly ($p < 0.0005$ and < 0.004 , respectively) as incubation temperature rose (Fig. 2a & b). Treatment with hsp70, however, produced disproportionate effects upon these two parameters.

The response of isolated cells at 37°C for 20 hours to hsp70 showed a significant increase ($p < 0.05$) in viability at or above 10 ng hsp70 per 10^3 cells (Fig. 3), compared to cells without added hsp. No change in viability occurred even with a ten-fold increase in the dose to 100 ng hsp70 per 10^3 cells. Temperature-response studies showed 10 ng hsp70 per 10^3 cells increased cell viability ($p < 0.05$) after storage for 20 hours at all three temperatures tested, with the greatest effect present at 37°C (Fig. 4). Based on these results, the optimum temperature for resolution of long-term (i.e., 20 hours) effects of added hsp was 37°C . In contrast, no effect of hsp70 on lysosomal membrane integrity was evident for the doses of added hsp or temperature range tested (Fig. 5). Studies at 37°C of three control proteins tested individually for non-specific exogenous effects each failed to show a maintenance of viability or

-20-

lysosomal membrane integrity, at either normal or ten times normal physiological concentrations.

C. DISCUSSION

The data presented here showed that exogenous hsp70 can enhance arterial cell survival. The use of a relatively long test period at a physiological temperature as the stress parameter appears unique to the study. Previous hsp studies have used brief periods (15-90 minutes) at relatively high temperatures (42-45°) to stress cells or animals, M. Schlesinger et al., Cold Spring Harbor Laboratory, 1982; M. Pardue et al., Alan R. Liss, Inc. (1989). In contrast, atherosclerotic plaques represent a system of chronic, multiple stresses. To more closely parallel these conditions, and especially those found in the necrotic core of a plaque, the present studies stressed cells by a combination of enzymatic cell release, hypoxia, low amino acid levels, and longer incubation periods.

Statistical differences were not observed in the test responses between normal and diseased arterial cell isolates. This may reflect the limited population size of this study, and/or the limited extent of atherosclerosis, i.e., the lack of arterionecrosis in these animals. Additionally, the procedure employed for cell release and the test conditions applied in this study may have caused a maximal hsp response for both normal and diseased cell isolates, masking differences in hsp responses present in vivo. The large proportion of normal smooth muscle cells found in even the most diseased aortas might also have a masking effect. The lack of differences could also reflect the potential point of action for exogenous hsp. If hsp affects viability via plasmalemma effector sites whose composition or number do not change during atherogenesis, the reaction cells to exogenous hsp would be the same regardless of their level of lipid load. Thus, the

-21-

results given here indicate a possible common pathway for the effect of exogenous hsp on arterial cells.

5 Viability and lysosomal membrane integrity are well correlated normally over a range of temperatures (Fig. 1), but have discordant responses to exogenous hsp70. The positive effect of added hsp70 on viability of cell isolates was initiated by as little as 10 ng/10³ cells and, once a significant effect was obtained, a ten fold increase in hsp concentration failed to induce further changes in cell viability (Fig. 3). This 10 increase occurred over a range of temperatures, but was most significant at 37°C (Fig. 4), possibly due to a maximal activation of degradative enzymes in the cells under study at this temperature.

15 In contrast to cellular viability, lysosomal membrane integrity was not significantly changed by exogenous hsp70 (Fig. 5). This observation may reflect a time-dependent factor yet to be determined. Figure 5 indicates that a decline in structure-linked lysosomal 20 latency with temperature occurred for samples both with and without added hsp. If lysosomal NABA latency is an earlier marker than viability for membrane integrity in this system, measurements at time points before 20 hours may reveal changes in latency across all temperatures 25 which are comparable to later changes in viability. To address this, time response studies are currently underway. Alternately, hsp70 may affect cell viability by a mechanism more specific than general cell membrane stabilization. If so, structure-linked lysosomal latency 30 may be affected independently of viability or be unaffected by exogenous hsps.

EXAMPLE 2

Protection of Nerve Tissue with HSP70

35 This experiment was conducted to demonstrate the use of hsp70 to protect nerve tissue against damage using light damage in the rat retina as a model system. Procedures were essentially as described in M. Barbe et

-22-

al., Science 241, 1817 (1988). hsp70 was as described in connection with Example 1 above.

Two groups of three rats each received an injection into the vitreous chamber of the right eye of a saline solution that contained either 2 μ g or 10 μ g of purified hsp70. These rats also received in the left eye an injection of the saline solution alone to control for any effect the injection itself might have. A third group of two rats were not injected and served as untreated controls. All three groups were exposed to 175-200 foot-candles of fluorescent light beginning four hours after the injections and continuing for 24 hours. Two weeks after the light exposure, the eyes of each rat were prepared for routine histology and the number of surviving photoreceptors in each eye determined by standard techniques. The difference in surviving photoreceptors between the right and left retinas was then calculated. A protective effect of the injected hsp70 is indicated when that difference is significantly greater than zero. On the other hand, if there was no effect of the injected hsp70, the loss of photoreceptors from the right and left eyes should average out to the same, giving a right-left difference that is not significantly different from zero.

Results are summarized in Figure 6. Based on a number of statistical comparisons, the group that received the 10 μ g dose of Hsp70 showed significant protection of the retinal photoreceptors against the light damage ($p<.05$), with the right eye having about 36% more photoreceptors than the left eye. The group that received the 2 μ g dose of Hsp70 showed a trend in the same direction as the higher dose group, but it did not attain statistical significance with the small number of subjects tested.

The foregoing examples are illustrative of the present invention, and are not to be construed as limiting thereof. The invention is defined by the

WO 91/15219

PCT/US91/02363

-23-

following claims, with equivalents of the claims to be included therein.

-24-

THAT WHICH IS CLAIMED IS:

1. A method of combating mortality in a cell under stress, comprising contacting hsp70 to the cell in an amount effective to enhance the survival of that cell.

2. A method according to claim 1, wherein
5 said hsp70 is animal hsp70.

3. A method according to claim 1, wherein
said hsp70 is plant hsp70.

4. A method according to claim 1, wherein
said hsp70 is bacterial hsp70.

- 10 5. A method according to claim 1, wherein
said hsp70 is mammalian hsp70.

6. A method according to claim 1, wherein
said cell is a plant cell.

- 15 7. A method according to claim 1, wherein
said cell is an animal cell.

8. A method according to claim 1, wherein
said cell is a bacterial cell.

9. A method according to claim 1, wherein
said cell is a mammalian cell.

- 20 10. A method according to claim 1, wherein
said cell is an arterial cell.

11. A method according to claim 1, wherein
said cell is a nerve cell.

-25-

12. A method according to claim 1, wherein said cell is maintained in vitro and said contacting step is carried out in vitro.

5 13. A method of combating mortality in a tissue under stress, comprising contacting hsp70 to the tissue in an amount effective to enhance the survival of cells residing in that tissue.

14. A method according to claim 13, wherein said hsp70 is animal hsp70.

10 15. A method according to claim 13, wherein said hsp70 is mammalian hsp70.

16. A method according to claim 13, wherein said tissue is mammalian tissue.

15 17. A method according to claim 13, wherein said tissue is arterial tissue.

18. A method according to claim 13, wherein said tissue is nerve tissue.

20 19. A method according to claim 13, wherein said tissue is maintained in vitro and said contacting step is carried out in vitro.

25 20. A method of combating atherosclerosis in a human or animal subject in need of such treatment, comprising administering the subject hsp70 in an amount effective to reduce necrosis in arterial plaques residing in the subject.

21. A method according to claim 20, wherein said administering step is carried out by intravenous injection.

-26-

22. A method of combating arterial restenosis after angioplasty in a human or animal subject in need of such treatment, comprising administering arterial tissue residing in the subject in need of such treatment hsp70 in a restenosis-combating amount.

5

23. A method of combating nerve damage in a human or animal subject in need of such treatment, comprising administering the subject hsp70 in an amount effective to enhance the survival of nerve cells under stress.

10

24. A method according to claim 24, wherein said stress is anoxic stress.

25. A method according to claim 24, wherein said stress is anoxic stress arising from a stroke.



15

26. A pharmaceutical composition comprising a therapeutically effective amount of hsp70 in a pharmaceutically acceptable formulation.

27. A pharmaceutical composition according to claim 26, wherein said hsp70 is animal hsp70.

20

28. A pharmaceutical composition according to claim 27, wherein said hsp70 is mammalian hsp70.

FIG. 1.FIG. 2.

2/3

FIG. 3.





FIG. 4.






FIG. 5.

INTRAVITREAL INJECTION OF HSP70 PROTECTS RETINA FROM LIGHT DAMAGE




FIG. 6.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/02363

I. CLASSIFICATION OF SUBJECT MATTER // Subsequent classification symbols: A61K 37/00

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC(5): A61K 37/00; C07K 3/00, 13/00, 15/00, 17/00
U.S. CL.: 514/12, 21; 530/350

II FIELDS SEARCHED

Minimum Documentation Searched *

Classification System 1 Classification System 2

U.S. | 514/12, 21; 530/350

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched *APS, Medline; search terms: heat-shock proteins, isolation, purification,
pharmacology, hsp, hsp70

III. DOCUMENTS CONSIDERED TO BE RELEVANT *

Category *	Citation of Document. ** with indication, where appropriate, of the relevant passages ***	Relevant to Claim No. ****
X,P	Archives of Biochemistry and Biophysics, Volume 280, No. 1, issued July 1990, D. MACRJAK ET AL., "Isolation and characterization of human HSP70 expressed in <u>Escherichia coli</u> ", pages 53-60, see abstract and page 54.	26-28
X A	Journal of Cellular Physiology, Volume 140, issued September 1989, V. GUERRIERO, JR. ET AL., "HSP70-related proteins in bovine skeletal muscle", pages 471-477, see abstract, pages 472-474, Figure 4.	26-28 1,2,5,12
X A	Molecular and Cellular Biology, Volume 8, No. 2, issued February 1988, R.L. ALLEN ET AL., "A novel hsp70-like protein (P70) is present in mouse spermatozoic cells", pages 828-832, see abstract, pages 829-830, Figure 4.	26-28 1,2,5,12
X	Journal of Chromatography, Volume 481, issued 03 November 1989, T. HATAYAMA ET AL., "Separation of rat liver HSP70 and HSP71 by high performance liquid chromatography with a hydroxylapatite column", pages 403-410, see abstract, page 404, Figs. 1-2.	26-28

(cont.)

* Special categories of cited documents: *

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may "now" contain new information which is cited to establish the date of the priority claim. The citation or other special reason (if any) is specified

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

T* later document published after the international filing date or priority date but not so early as to cast doubt on the claimed priority date, or so late as to affect the understanding of the document or its relationship to the invention

X** document of particular relevance, the claimed invention cannot be considered valid if it is considered to be anticipated by such document

Y*** document of particular relevance, the claimed invention cannot be considered valid if it is considered to be anticipated when the document is combined with one or more other such documents, such combination being of common general common sense

Z**** document member of the same patent family

IV. CERTIFICATION


Date of the Actual Completion of the International Search

Date of Signing of PCT International Search Report

14 June 1991

10 JUL 1991

International Search and Assessment


Richard Ekstrom

ISA/US

(vsh)

International Application No. PCT/US91/02363

III DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category*	Character of Document with indication, where appropriate, of the inventor/publisher	Priority Date or Claim No.
X	FASEB Journal, Volume 4, issued 28 February 1990, A.D. JOHNSON ET AL. , "Time-correlated cytoprotection by 70kD heat shock protein in arterial cells during metabolic stress", page A1032, see entire document.	1,2,5,12, 26-28
V	FASEB Journal, Volume 4, issued 28 February 1990, P.A. BERBERIAN ET AL. , "Exogenous 70kD heat shock protein increases survival of normal and athero- matous arterial cells", A1031, see entire document.	1,2,5,12, 26-28
Y	Journal of Cellular Physiology, Volume 138, No. 2, issued February 1989, L.E. HIGHTOWER ET AL. , "Select- ive release from cultured mammalian cells of heat- shock (stress) proteins that resemble glia-axon transfer proteins", pages 257-266, see entire docu- ment.	1,2,5,12

International Application No. PCT/US91/02363

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

X.P Atherosclerosis, Volume 84, issued October 1990,
A.D. JOHNSON ET AL.. "Effect of heat shock proteins
on survival of isolated aorticcells from normal
and atherosclerotic cynomolgous macaques". pages
111-119, see entire document. 1,2,5,12.
26-28

Y Cancer Research, Volume 49, issued 15 March 1989,
N.F. MIVECHI ET AL., "Effects of heat shock proteins
(Mr 70,000) on protein and DNA synthesis at elevated
temperatures in vitro", pages 1492-1496, see entire
document. 1,2,5,12.
26-28

(cont.)

V. OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. Claim numbers _____, because they relate to subject matter¹⁴ not required to be searched by this Authority, namely:

2 Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out¹⁵, specifically:

3 Claim numbers _____, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING¹⁶

This International Searching Authority found multiple inventions in this international application as follows:

See attachment

1 As all required additional search fees were timely paid by the applicant, this international search report covers all selectable claims of the international application.

2 As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3 No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers: 1, 2, 5, 12, 26-28.

4 As all searchable claims could be searched without effort, applying an additional fee, the International Authority did not make payment of any additional fee.

Remarks on Protest

The additional search fees were accompanied by applicant's protest.

No protest accompanied the payment of additional search fees.

Serial No. PCT/US91/02363
Art Unit 1898

1

VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

The claims present a plurality of mutually exclusive independent inventions as follows:

5 I. Claims 1 - 12, and 26-28, drawn to a method and composition of hsp70 for treating a cell under stress.

Note that the following are independent and distinct species pertinent to the invention of Group I where a) is the first species and will be searched with claims 1 and 12 in the event 10 that no other fees are paid. Note that a search of any other additional species within Group I requires payment of additional fees.

- 15 a) The hsp70 is animal/mammalian hsp70 (claims 2 and 5).
- b) The hsp70 is plant hsp70 (claim 3).
- c) The hsp70 is bacterial hsp70 (claim 4).
- d) The cell treated is a plant cell (claim 6).
- e) The cell treated is a bacterial cell (claim 8).
- f) The cell treated is an animal/mammalian/arterial cell (claims 7, 9, and 10).
- 20 g) The cell treated is an animal/mammalian/nerve cell (claims 7, 9, and 11).

30 II. Claims 13-15 and 19, drawn to a method of using hsp70 for treating a tissue under stress.

Note that the following are independent and distinct species pertinent to the invention of Group II where h) is the first species and will be searched with claims 13-15 and 19 upon

Serial No. PCT/US91/02363
Art Unit 189B

payment of the requisite fees for Group II. Note that a search of any other additional species other than h) within Group II requires payment of additional fees.

5 h) The method of treating mammalian/arterial tissue (claims 16 and 17).

i) The method of treating mammalian/nerve tissue (claims 16 and 18).

10 III. Claims 20-21, drawn to a method for treating atherosclerosis with hsp70.

IV. Claim 22, drawn to a method for treating arterial restenosis after angioplasty with hsp70.

V. Claims 23-25, drawn to a method for treating nerve damage with hsp70.

5 The inventions are distinct, each from the other because of the following reasons:

Animal, plant, and bacterial hsp70 are different species, one of which is not obvious over the other. Animal, plant, and bacterial cells are different species, one of which is not obvious over the other, and treatment with hsp70 is likely to entail different methodologies due to the biochemical differences between these cell types, especially the presence or absence and type of cell wall present. Nerve and arterial cells/tissue also are different species, one of which is not obvious over the other, i.e. these cell types have different functions and biochemical responses. The treatment of cells versus tissues is considered to comprise different inventions because a tissue

Serial No. PCT/US91/02363
Art Unit 1898

represents an integrative collection of cells which is able to respond in a coordinated manner that differs from the response of a simple collection cells (such as in cell culture). The treatment of atherosclerosis, restenosis, and nerve damage in a human/animal are different species, one of which is not obvious over the other, and are in vivo procedures; in vitro procedures, such as can be carried out with cells or isolated tissues, are not predictive of in vivo success for treatments with hsp70.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, a holding of lack of unity as indicated is proper.